EOS 789
Alternative Names: AP-306 ; EOS-789Latest Information Update: 12 Dec 2025
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Shanghai Alebund Pharmaceuticals
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Phosphate transport protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 08 Dec 2025 Phase-II clinical trials in Hyperphosphataemia in USA (PO) prior to December 2025 (Shanghai Alebund Pharmaceuticals, December 2025)
- 08 Dec 2025 NMPA approves IND application for EOS 789 in Hyperphosphataemia prior to December 2025 (Shanghai Alebund Pharmaceuticals, December 2025)
- 08 Dec 2025 US FDA approves IND application for EOS 789 in Hyperphosphataemia prior to December 2025 (Shanghai Alebund Pharmaceuticals, December 2025)